Phase 1 N=32 Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
Malignant Glioma
Primary: Maximum Tolerated Dose (MTD) — 200 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=34 Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Primary: Incidence and Severity of Adverse Events — 1; 0; 3; 2 Participants
Phase 1 N=35 Behavioral Pharmacology of THC and D-limonene
D-limonene and THC Pharmacodynamics
Primary: Mean Peak Change From Baseline Anxiety as Assessed by the Drug Effect Questionnaire (DEQ) — -1.2; 13.8; 18.7; -1.9 score on a scale
Phase 1 N=20 Gut Butyrate and Blood Pressure in African Americans
Hypertension
Primary: Mean Daytime Blood Pressure — 137.5; 132.9; 128.2 mmHg
Phase 1 N=29 A Study of LY3337641 in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641 — 66.7; 64.9; 56.8; 65.5 nanograms per milliliter (ng/mL)
Phase 1 N=88 First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
Healthy
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Discontinuation of Study Treatment — 13; 6; 5; 3…
Phase 1 N=72 A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
Solid Tumor
Primary: Recommended Phase 2 Dose of LY3022855 Combined With Durvalumab (Maximum Tolerated Dose [MTD]) — 100 milligrams (mg)
Phase 1 N=32 Trial to Evaluate L9LS in Healthy Adults
Malaria
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of L9LS Product Administration — 2; 3; 3; 4 Participants
Phase 1 N=10 Clearance of 25-hydroxyvitamin D in Cystic Fibrosis
Cystic Fibrosis
Primary: Metabolic Clearance of D6-25(OH)D3 — 397; 342 mL/day
Phase 1 N=133 Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event (AE) — 100.0; 82.2; 95.3; 90.9 Percentage of Participants — p=0.004
Phase 1 N=23 Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Stage II Non-Small Cell Lung Cancer · Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of the Combination of Pembrolizumab With Paclitaxel, Carboplatin and Radiation Therapy According to the…
Phase 1 N=66 Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
Deep Vein Thrombosis · Venous Thromboembolism
Primary: Pharmacokinetic Parameter of Apparent Systemic Clearance (CL/F) — 42.9 L/h
Phase 1 N=22 A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0 Participants
Phase 1 N=12 Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir
Healthy Participant
Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07321332 — 2210; 1300 nanogram per milliliter (ng/mL) — p=0.05
Phase 1 N=15 STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS
Neoplasms
Primary: Maximum Observed Concentration (Cmax) of Talazoparib Following Single Oral Dose — 8.506 nanogram/milliliter (ng/mL)